Rituximab biosimilar-Research Grade (MALS verified)
Product Sizes
100 ug
CD0-M36-100UG
500 ug
CD0-M36-500UG
About this Product
- SKU:
- CD0-M36
- Buffer:
- PBS
- Clonality:
- Recombinant Monoclonal
- Extra Details:
- B-lymphocyte antigen CD20 is also known as B-lymphocyte surface antigen B1, Leukocyte surface antigen Leu-16, Membrane-spanning 4-domains subfamily A member 1 and MS4A1, is an activated-glycosylated phosphoprotein expressed on the surface of all B-cells beginning at the pro-B phase (CD45R+, CD117+) and progressively increasing in concentration until maturity. CD20 is expressed on all stages of B cell development except the first and last; it is present from late pro-B cells through memory cells, but not on either early pro-B cells or plasma blasts and plasma cells. It is found on B-cell lymphomas, hairy cell leukemia, B-cell chronic lymphocytic leukemia, and melanoma cancer stem cells. The protein has no known natural ligand and its function is to enable optimal B-cell immune response, specifically against T-independent antigens. It is suspected that it acts as a calcium channel in the cell membrane. CD20 / MS4A1 is the target of the monoclonal antibodies (mAb) rituximab, Ibritumomab tiuxetan, and tositumomab, which are all active agents in the treatment of all B cell lymphomas and leukemias. Defects in CD20 / MS4A1 are the cause of immunodeficiency common variable type 5 (CVID5); also called antibody deficiency due to CD20 defect. CVID5 is a primary immunodeficiency characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections and an inability to mount an antibody response to antigen.
- Immunogen:
- CD20
- Physical State:
- Powder
- Purification:
- 95%
- Reactivities:
- Mouse
- Shipping Conditions:
- Ambient
- Storage Conditions:
- -20[o]C
- Supplier:
- ACRO Biosystems
- Type:
- Antibody: Biosimilar Antibody
